ID   WM1366
AC   CVCL_6789
SY   WM-1366; WM 1366; WC00078; EST70
DR   cancercelllines; CVCL_6789
DR   Coriell; WC00078
DR   Cosmic; 1047650
DR   Cosmic; 1155539
DR   Cosmic; 1665010
DR   Cosmic; 2163800
DR   ESTDAB; ESTDAB-070
DR   GEO; GSM109027
DR   GEO; GSM185178
DR   GEO; GSM185179
DR   GEO; GSM185180
DR   GEO; GSM185181
DR   GEO; GSM188064
DR   GEO; GSM188116
DR   GEO; GSM188189
DR   GEO; GSM188204
DR   GEO; GSM188217
DR   GEO; GSM188231
DR   GEO; GSM188261
DR   GEO; GSM188280
DR   GEO; GSM188289
DR   GEO; GSM188320
DR   GEO; GSM952594
DR   GEO; GSM1507941
DR   IARC_TP53; 26077
DR   Progenetix; CVCL_6789
DR   Rockland; WM1366-01-0001
DR   SKY/M-FISH/CGH; 4947
DR   Wikidata; Q54994172
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=19340423;
RX   PubMed=23851445;
RX   PubMed=25502142;
RX   PubMed=25645078;
RX   PubMed=25728708;
RX   PubMed=28196595;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*32:01,32:01; B*41:01,41:01; C*17:01,17:01; DPB1*03:01,03:01; DQB1*02:01,02:01; DRB1*03:01:02,03:01:02 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro48Leu (c.143C>T); Zygosity=Unspecified (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; PubMed=25645078; PubMed=25728708; Wistar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D5S818: 12,13->13 and D7S820: 11,12->12.
CC   Misspelling: Wn1366; Cosmic=1665010.
CC   Discontinued: Coriell; WC00078; probable.
CC   Derived from site: In situ; Forearm, skin; UBERON=UBERON_0003399.
ST   Source(s): ESTDAB=ESTDAB-070; Wistar
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,13
ST   D16S539: 12,13
ST   D18S51: 12,16
ST   D19S433: 14,15
ST   D21S11: 28,30
ST   D2S1338: 20,22
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 12
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   79Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 33
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25502142; DOI=10.1038/ncomms6712;
RA   Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C.,
RA   Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H.,
RA   Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G.,
RA   Graeber T.G., Ribas A., Lo R.S., Peeper D.S.;
RT   "Low MITF/AXL ratio predicts early resistance to multiple targeted
RT   drugs in melanoma.";
RL   Nat. Commun. 5:5712.1-5712.15(2014).
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W.,
RA   van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A.,
RA   Beijnen J.H., Altelaar A.F.M., Peeper D.S.;
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//